Cargando…

Continuum Crystallization Model Derived from Pharmaceutical Crystallization Mechanisms

[Image: see text] The crystallization mechanisms of organic molecules in solution are not well-understood. The mechanistic scenarios where crystalline order evolves directly from the molecularly dissolved state (“classical”) and from initially formed amorphous intermediates (“nonclassical”) are sugg...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsarfati, Yael, Biran, Idan, Wiedenbeck, Eduard, Houben, Lothar, Cölfen, Helmut, Rybtchinski, Boris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161475/
https://www.ncbi.nlm.nih.gov/pubmed/34079905
http://dx.doi.org/10.1021/acscentsci.1c00254
_version_ 1783700519617822720
author Tsarfati, Yael
Biran, Idan
Wiedenbeck, Eduard
Houben, Lothar
Cölfen, Helmut
Rybtchinski, Boris
author_facet Tsarfati, Yael
Biran, Idan
Wiedenbeck, Eduard
Houben, Lothar
Cölfen, Helmut
Rybtchinski, Boris
author_sort Tsarfati, Yael
collection PubMed
description [Image: see text] The crystallization mechanisms of organic molecules in solution are not well-understood. The mechanistic scenarios where crystalline order evolves directly from the molecularly dissolved state (“classical”) and from initially formed amorphous intermediates (“nonclassical”) are suggested and debated. Here, we studied crystallization mechanisms of two widely used analgesics, ibuprofen (IbuH) and etoricoxib (ETO), using direct cryogenic transmission electron microscopy (cryo-TEM) imaging. In the IbuH case, parallel crystallization pathways involved diverse phases of high and low density, in which the instantaneous formation of final crystalline order was observed. ETO crystallization started from well-defined round-shaped amorphous intermediates that gradually evolved into crystals. This mechanistic diversity is rationalized by introducing a continuum crystallization paradigm: order evolution depends on ordering in the initially formed intermediates and efficiency of molecular rearrangements within them, and there is a continuum of states related to the initial order and rearrangement rates. This model provides a unified view of crystallization mechanisms, encompassing classical and nonclassical pictures.
format Online
Article
Text
id pubmed-8161475
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-81614752021-06-01 Continuum Crystallization Model Derived from Pharmaceutical Crystallization Mechanisms Tsarfati, Yael Biran, Idan Wiedenbeck, Eduard Houben, Lothar Cölfen, Helmut Rybtchinski, Boris ACS Cent Sci [Image: see text] The crystallization mechanisms of organic molecules in solution are not well-understood. The mechanistic scenarios where crystalline order evolves directly from the molecularly dissolved state (“classical”) and from initially formed amorphous intermediates (“nonclassical”) are suggested and debated. Here, we studied crystallization mechanisms of two widely used analgesics, ibuprofen (IbuH) and etoricoxib (ETO), using direct cryogenic transmission electron microscopy (cryo-TEM) imaging. In the IbuH case, parallel crystallization pathways involved diverse phases of high and low density, in which the instantaneous formation of final crystalline order was observed. ETO crystallization started from well-defined round-shaped amorphous intermediates that gradually evolved into crystals. This mechanistic diversity is rationalized by introducing a continuum crystallization paradigm: order evolution depends on ordering in the initially formed intermediates and efficiency of molecular rearrangements within them, and there is a continuum of states related to the initial order and rearrangement rates. This model provides a unified view of crystallization mechanisms, encompassing classical and nonclassical pictures. American Chemical Society 2021-04-23 2021-05-26 /pmc/articles/PMC8161475/ /pubmed/34079905 http://dx.doi.org/10.1021/acscentsci.1c00254 Text en © 2021 The Authors. Published by American Chemical Society Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Tsarfati, Yael
Biran, Idan
Wiedenbeck, Eduard
Houben, Lothar
Cölfen, Helmut
Rybtchinski, Boris
Continuum Crystallization Model Derived from Pharmaceutical Crystallization Mechanisms
title Continuum Crystallization Model Derived from Pharmaceutical Crystallization Mechanisms
title_full Continuum Crystallization Model Derived from Pharmaceutical Crystallization Mechanisms
title_fullStr Continuum Crystallization Model Derived from Pharmaceutical Crystallization Mechanisms
title_full_unstemmed Continuum Crystallization Model Derived from Pharmaceutical Crystallization Mechanisms
title_short Continuum Crystallization Model Derived from Pharmaceutical Crystallization Mechanisms
title_sort continuum crystallization model derived from pharmaceutical crystallization mechanisms
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161475/
https://www.ncbi.nlm.nih.gov/pubmed/34079905
http://dx.doi.org/10.1021/acscentsci.1c00254
work_keys_str_mv AT tsarfatiyael continuumcrystallizationmodelderivedfrompharmaceuticalcrystallizationmechanisms
AT biranidan continuumcrystallizationmodelderivedfrompharmaceuticalcrystallizationmechanisms
AT wiedenbeckeduard continuumcrystallizationmodelderivedfrompharmaceuticalcrystallizationmechanisms
AT houbenlothar continuumcrystallizationmodelderivedfrompharmaceuticalcrystallizationmechanisms
AT colfenhelmut continuumcrystallizationmodelderivedfrompharmaceuticalcrystallizationmechanisms
AT rybtchinskiboris continuumcrystallizationmodelderivedfrompharmaceuticalcrystallizationmechanisms